Compare Ascendis Pharma A/S (ASND) vs BHP Billiton Limited (BHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs BHP Billiton Limited — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while BHP Billiton Limited trades at $81.71 (market cap $204.10B). The key difference: BHP Billiton Limited is far larger — about 11.5× Ascendis Pharma A/S's market cap, and BHP Billiton Limited pays a 3.26% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BHP | |
|---|---|---|
Market Cap | $17.74B | $204.10B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $93.15 |
52-Week Low | $163.32 | $50.37 |
Enterprise Value | $18.11B | $218.31B |
Dividend Yield | — | 3.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BHP trades at $81.68, up 2.21% today, with a bearish technical signal from moving averages. The company reported Q4 2025 EPS of $2.24, missing the $2.41 estimate, but beat in Q2 2025. Recent news highlights a potential strike at Port Hedland threatening daily revenue and a $2.3 billion writedown at the Jansen potash project due to cost overruns. Revenue for 2024 was $55.66 billion with a net income margin of 18.97%, while the P/E ratio stands at 20.29.
The outlook is mixed; strong profitability and cash flow support value, but operational disruptions and project cost increases pose near-term risks. Analyst consensus is cautious with 64.52% hold ratings. Investors should weigh solid fundamentals against execution challenges and commodity price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →
